

Preferred Drug List Announcement

MO HealthNet Division (MHD) is continuing the state-specific Preferred Drug List (PDL) evaluation process. Drugs/Drug classes for review for the upcoming quarter are identified at each of the quarterly meetings of the Drug Prior Authorization Committee and also posted on the Division’s web page at <http://dss.mo.gov/mhd/cs/pharmacy/pdf/pdla.pdf>.

MO HealthNet Division’s clinical team will conduct the clinical reviews of the drug products under evaluation each quarter. For preferred status consideration for your product, a more detailed review request should be presented to MHD.

- All clinical information for consideration should be forwarded to Karen Powell at karen.powell@gainwelltechnologies.com. These submissions should generally follow the AMCP guideline format.
- Financial evaluations for these therapeutic class reviews are conducted by Gainwell Technologies, LLC. Companies wishing to discuss opportunities for supplemental rebates and/or the policy surrounding the PDL process should contact GWTContracting@gainwelltechnologies.com and Sandy Kapur, PharmD at sandy.kapur@gainwelltechnologies.com.
- If a public presentation is desired, please contact Carmen Burton at Carmen.M.Burton@dss.mo.gov or call (573) 751-6961.

The Drug PA Committee will convene at 10:00 a.m. on Tuesday, April 18, 2023.

Drug Therapeutic Class Name
Anti-infectives
<ul style="list-style-type: none"> • Antifungals for Onychomycosis • Antifungals for Thrush • Antivirals, General • Inhaled Antibiotics
Dermatologic agents
<ul style="list-style-type: none"> • Topical Agents for Actinic Keratosis • Topical Antibiotic/Benzoyl Peroxide Combinations • Topical Antifungals • Topical Antiparasitics, Treatment of Lice & Scabies • Topical Antivirals • Topical Corticosteroids • Topical Retinoids and Combinations
Endocrine and Metabolic Agents
<ul style="list-style-type: none"> • Androgenic Agents, Topical and Self-Injectable

Drug Therapeutic Class Name
Gastrointestinal
<ul style="list-style-type: none"> • Pancreatic Enzymes • Ulcerative Colitis Agents, Oral • Ulcerative Colitis Agents, Rectal
Ophthalmic
<ul style="list-style-type: none"> • Antibiotics, Fluoroquinolones • Antihistamines • Glaucoma, Alpha 2 Receptor Agonist and Carbonic Anhydrase Inhibitors (CAI) • Glaucoma, Prostaglandin Agonists • Glaucoma, Rho Kinase (ROCK) Inhibitors • Mast Cell Stabilizers • NSAIDS • "Soft" Corticosteroids
Otic preparations
<ul style="list-style-type: none"> • Fluoroquinolone & Combination Agents
Respiratory
<ul style="list-style-type: none"> • Anticholinergics, Long Acting • Anticholinergics, Short Acting & Combinations • Anticholinergics, Long-acting Beta Agonist (LABA) Combinations • Anticholinergics, LABA/Inhaled Corticosteroids (ICS) Combinations • Beta-Adrenergic Agents, Long-acting • Beta-Adrenergic Agents, Short-acting • Beta-Adrenergic Agonists, Short-acting Nebulized • Cough and Cold • ICS • ICS, ICS-LABA • Intranasal Antihistamines • Intranasal Corticosteroids • Leukotriene Receptor Modifiers • PDE4 Inhibitor for COPD, Oral • Second Generation Antihistamines • Second Generation Antihistamines & Decongestant Combination Agents • Self-injectable Epinephrine